Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate ganglion block plus esketamine for prevention of postpartum depression after cesarean section
ChiCTR2600121983Phase 4Not yet recruiting
- Sponsor
- Ganzhou People's Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postpartum depression (PPD) (3 arms), sponsored by Ganzhou People's Hospital. Primary endpoints: Serum cortisol, Adrenocorticotropic hormone (ACTH) and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on ChiCTR2600121983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121983.